Scholarlink

Dendritic cell (DC) cancer vaccines are used to circumvent the problem that DCs in patients with cancer usually do not mature properly in the cancer environment. Peripheral DCs are fewer in number and hard to isolate cleanly. Instead, autologous DCs can be matured from monocyte precursors obtained by apheresis and elutriation from peripheral blood. Here, we describe procedures for harvesting cells, growing them into DCs, inducing antigen expression by pulsing them with antigenic peptides or inducing antigen expression by transducing them with antigens expressed by a recombinant adenovirus (or other viral vector), maturing them in vitro, and then administering them to patients.

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Dendritic Cell Cancer Vaccines: Clinical Production for Cancer Immunotherapy

  • 实验方案

  • 发表日期：

    2025年

查看全文
  • Hoyoung M. Maeng,
  • Purevdorj B. Olkhanud,
  • Mary Black,
  • Steve L. Highfill,
  • David F. Stroncek,
  • Jay A. Berzofsky

摘要

Dendritic cell (DC) cancer vaccines are used to circumvent the problem that DCs in patients with cancer usually do not mature properly in the cancer environment. Peripheral DCs are fewer in number and hard to isolate cleanly. Instead, autologous DCs can be matured from monocyte precursors obtained by apheresis and elutriation from peripheral blood. Here, we describe procedures for harvesting cells, growing them into DCs, inducing antigen expression by pulsing them with antigenic peptides or inducing antigen expression by transducing them with antigens expressed by a recombinant adenovirus (or other viral vector), maturing them in vitro, and then administering them to patients.